Precision Business Insights
Portfolio

 

Research Reports

Histone Deacetylase Inhibitors Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Histone Deacetylase Inhibitors Market

 

By Drug Class (Class I, Class II, Class III, Class IV), By Application (Neurology, Oncology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

 

Global histone deacetylase inhibitors market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024

 

Market Outline: Global Histone Deacetylase Inhibitors Market

Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers. Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases.

 

Market Dynamics: Global Histone Deacetylase Inhibitors Market

Rise in prevalence of cancers and neurological disorders drives the global histone deacetylase inhibitors market. Moreover, increase in the R&D activities for the cancer treatment and other diseases, rise in demand to improve effectiveness of newer treatment therapies, and promising pipeline drugs, are anticipated to fuel the global histone deacetylase inhibitors market. However, lack of favorable reimbursement policies and uncertainty issues and stringent regulations for the product approval are restrain the growth of histone deacetylase inhibitors market over the forecast years.

 

Market Scope: Global Histone Deacetylase Inhibitors Market

Histone deacetylase inhibitors market is segmented on the basis of drug class, application, and Distribution Channel

Based on the drug class, the market is segmented into the following:

  • Class I
  • Class II
  • Class III
  • Class IV

Based on the application, the market is segmented into the following:

  • Neurology
  • Oncology
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Regional Analysis: Global Histone Deacetylase Inhibitors Market

Geographically, global histone deacetylase inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America histone deacetylase inhibitors market is poised to grow at notable CAGR owing to increase in R&D for the development of newer drugs, rise in prevalence of cancer and neurological disorders, and high acceptance of HDAC products are expected to the boost the market. Europe histone deacetylase inhibitors market is rising due to increase in the aging population results to rise in prevalence of neurological disorders, grow in demand for advanced treatments, and pipeline drugs under the various stages of clinical trials are bolster the market. However, Asia Pacific histone deacetylase inhibitors market is poised to grow due to entry of market players into Asia Pacific countries with launch of newer products, rise in medical tourism for cancer treatment in Asia Pacific countries, and large patient pool are expected to offer healthy growth opportunities for the market.

 

Competition Assessment: Global Histone Deacetylase Inhibitors Market

Some of the players in the global histone deacetylase inhibitors market include:

  • Novartis AG (Switzerland)
  • AstraZeneca Plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Celgene Corporation (U.S.)
  • Eisai Co. Ltd. (Japan)
  • Merck & Co., Inc. (U.S.)
  • Acetylon Pharmaceuticals, Inc. (U.S.)
  • Celleron Therapeutics Ltd. (U.K.)
  • Innovation Pharmaceuticals, Inc. (U.S.)
  • Ranedis Pharmaceuticals (U.S.)

 

Notable Market Developments: Histone Deacetylase Inhibitors Market

  • In March 2017, AMO Pharma and Ranedis Pharmaceuticals entered into a collaboration to develop the RND-001, HDAC inhibitor, used in specific lysosomal storage disorders and neurodegenerative disorders

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (The USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Venezuela, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
  • Novartis AG (Switzerland)
  • AstraZeneca Plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Celgene Corporation (U.S.)
  • Eisai Co. Ltd. (Japan)
  • Merck & Co., Inc. (U.S.)
  • Acetylon Pharmaceuticals, Inc. (U.S.)
  • Celleron Therapeutics Ltd. (U.K.)
  • Innovation Pharmaceuticals, Inc. (U.S.)
  • Ranedis Pharmaceuticals (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

2,469.607,326.48
Clear selection

Select License Type

Databank 2,469.60
spinner
Single User 3,622.08
spinner
Multiple User 5,433.12
spinner
Corporate User 7,326.48
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials